- MUTYH-Associated Polyposis: What Your Colon-Cancer Risk Really Is (US & Canada)
- How MUTYH-Associated Polyposis Is Inherited
- Your Real Risk: Biallelic vs Monoallelic in Absolute Numbers
- Testing Options: 23andMe vs Clinical Diagnostic Testing
- Interpreting Your Results: Diagnosis, Carrier, or Uncertain
- Colonoscopy Surveillance and Early Detection
- Prevention, Chemoprevention, and Prophylactic Surgery
- Family Implications and Cascade Testing
- Psychosocial Impact: GINA, the Insurance Gap, and Disclosure
- Frequently Asked Questions
- Summary
- References
MUTYH-Associated Polyposis: What Your Colon-Cancer Risk Really Is (US & Canada)
This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.
My dad has MUTYH-associated polyposis. I keep wondering if I’m next, and how bad my colon-cancer odds really are.
That worry is incredibly common in the genetics clinic. Published research shows a family history raises the odds, but the inheritance pattern here is very specific, so it is not automatically destiny.
Honestly, even the idea of testing scares me. If I find out I’m a carrier, can I even handle that?
That is a very human reaction, and you are far from alone. Studies suggest the psychological impact of genetic testing is generally neutral to mild when it is paired with genetic counseling.
My wife and I have young kids. Will they just inherit this straight from me?
It is more nuanced than a simple yes, and the concept of cascade testing for at-risk relatives is well established in the clinical guidelines. We will walk through exactly what it means for your family.
And my 23andMe said nothing about it. Doesn’t that already mean I’m in the clear?
Not quite, and the FDA authorization itself says so. A consumer report is a screen, not a diagnosis, so we will walk step by step from your primary care doctor to a genetic counselor.
Bottom line: Since Al-Tassan and colleagues first tied faulty MUTYH copies to colon tumors in Nature Genetics in 2002, the science has become clear on one point and murky on another. People who inherit a broken MUTYH gene from both parents (biallelic) face a high lifetime colon-cancer risk and need close surveillance. People with just one broken copy (monoallelic) carry, at most, a small and still-debated increase. A 23andMe report is a screen, not a diagnosis. This guide translates the research into plain numbers and points you back to a clinician for every real decision.
What you’ll learn:
- How MUTYH-associated polyposis (MAP) is inherited, and why it differs from FAP
- Your real lifetime risk in absolute numbers, split by one mutation versus two
- Why a consumer DNA report cannot confirm or rule out this condition
- How surveillance, prevention, family testing, and your legal rights actually work
How MUTYH-Associated Polyposis Is Inherited
My dad has it, so did I just inherit it straight from him the way he got it?
Not from him alone, actually. MedlinePlus explains this is autosomal recessive, so it takes a broken copy from both parents to cause the condition, not just one from your father.
MUTYH-associated polyposis is an autosomal recessive condition. That means a person must inherit a broken MUTYH gene from both parents (called biallelic) to develop it. Inheriting just one broken copy is not enough to cause the classic condition.
The MUTYH gene carries instructions for a repair enzyme. This enzyme performs “base-excision repair,” meaning it finds and fixes DNA bases that toxic oxygen molecules have damaged. Think of it as a spell-checker that catches one specific typo before your cells copy it forever.
When both copies of MUTYH fail, that spell-checker is offline. A signature error — a G:C→T:A swap — then piles up in growth-control genes like APC and KRAS. Those errors drive the colon to grow many polyps, which are small tissue lumps that can turn cancerous over time.
Al-Tassan and colleagues discovered this in 2002. They studied one family with many colon adenomas but no inherited APC mutation. In their tumors, 15 of 18 APC-inactivating mutations were the tell-tale G:C→T:A type — the first human disorder ever traced to broken base-excision repair.
This is where MAP differs sharply from familial adenomatous polyposis (FAP). FAP is autosomal dominant, meaning one broken APC copy is enough to cause it. The table below contrasts the two.
| Feature | MUTYH-associated polyposis (MAP) | Familial adenomatous polyposis (FAP) |
|---|---|---|
| Gene | MUTYH | APC |
| Inheritance | Autosomal recessive (need two broken copies) | Autosomal dominant (one broken copy) |
| Typical polyp count | Ten to a few hundred | Hundreds to thousands |
| Colon-cancer risk | High but variable (see next section) | ~90% by age 45 in classic FAP |
So who do I even go to first to sort out whether it’s MAP or that FAP thing?
Start with your primary care doctor for a referral to a certified genetic counselor, whom you can also find via NSGC.org. They distinguish MAP from FAP by gene, since the ACG guideline treats them as separate syndromes.
If a close relative has been diagnosed, ask your primary care doctor for a referral to a genetic counselor. You can find a certified counselor through NSGC.org.
Section recap: MAP needs two broken MUTYH copies and stems from failed DNA repair. FAP needs only one broken APC copy and usually causes far more polyps.
Your Real Risk: Biallelic vs Monoallelic in Absolute Numbers
If I do carry this, am I basically guaranteed to get colon cancer? That’s the number that scares me.
It depends entirely on whether you have one broken copy or two, and people confuse those constantly. GeneReviews reports very different lifetime risks for each, and this section lays out the actual numbers.
The single biggest source of confusion is the gap between having two broken copies and having one. The research treats them very differently, so this section splits them clearly.
Biallelic carriers (two broken copies) face a genuinely high lifetime colon-cancer risk. Without surveillance, that risk is reported at 80% to 90% over a lifetime. By age 60, GeneReviews cites a risk of 43% to 63%. Cohort data summarized by the National Cancer Institute place the figure around 35% to 53% in the studied groups.
To make that concrete: a lifetime risk of 80% means that out of 100 biallelic people with no monitoring, roughly 80 would develop colon cancer. That is why surveillance matters so much — it is not a formality.
Monoallelic carriers (one broken copy) are a very different story, and this is where content-farm pages often frighten people needlessly. About 1% to 2% of the general population carries a single MUTYH mutation. A meta-analysis by Win and colleagues found a pooled odds ratio of 1.15 for colon cancer — with a 95% confidence interval of 0.98 to 1.36. Because that interval crosses 1.0, the result is borderline and not statistically firm.
| Carrier status | Broken copies | Lifetime colon-cancer risk | What it means for you |
|---|---|---|---|
| Biallelic (MAP) | Two | 80–90% without surveillance; 43–63% by age 60 | High risk; needs a surveillance plan |
| Monoallelic (carrier) | One | At most a small, uncertain increase (OR ~1.15, CI 0.98–1.36) | Usually not managed as high-risk |
A registry cohort by Win and colleagues found that a single carrier’s slightly higher risk was driven mostly by family history, not the lone MUTYH variant itself. In plain terms, one broken copy alone is not a colon-cancer sentence.
OK, but how do I find out which one of those numbers actually applies to me?
A genetic counselor applies these population figures to your specific result, since the Win meta-analysis shows why one-copy risk is so easy to overstate. Ask your doctor for a referral before you assume the worst.
Only a clinician can apply these population numbers to your personal picture. Ask a genetic counselor to interpret what your specific result means.
Section recap: Two broken copies mean a high, action-worthy risk. One broken copy means, at most, a small and debated increase that usually does not require high-risk management.
Testing Options: 23andMe vs Clinical Diagnostic Testing
I already spat in a 23andMe tube. Isn’t that basically the same as a real genetic test?
Not the same tool, and the FDA authorization says so explicitly. The 23andMe report checks only two founder variants, so a clinical panel that sequences the whole gene answers a very different question.
This distinction can change what you do next, so it deserves care. A consumer test and a clinical test are not the same tool.
23andMe’s Genetic Health Risk report for MAP was cleared by the FDA on January 22, 2019, through the 510(k) pathway. But it checks only the two most common variants, Y179C and G396D, which are most common in people of Northern European descent. These two account for most pathogenic MUTYH alleles in that group but do not cover the whole gene.
The FDA authorization is explicit: this report is not a diagnostic test. It does not diagnose disease and should not be used to make medical decisions. So a “not detected” consumer result cannot rule out MAP — the mutation you carry might simply be one the test never looks at.
There is a second reason to confirm consumer results in a clinical lab. A study by Tandy-Connor and colleagues found that 40% of variants flagged as risk-related in DTC raw data were false positives when a clinical laboratory rechecked them. Several were later reclassified as harmless.
| Feature | 23andMe (DTC) | Clinical diagnostic panel |
|---|---|---|
| Variants checked | Two founder variants only | Full MUTYH gene sequencing |
| Diagnostic? | No — a screen only | Yes, ordered through a clinician |
| A negative result means | Does not rule out MAP | Far more complete answer |
| Ordered by | Consumer, no prescription | Physician or genetic counselor |
So if I want the real answer, how do I even get that clinical test ordered?
Your physician or a genetic counselor orders full gene sequencing, which matters because Tandy-Connor’s study found forty percent of consumer risk variants were false positives on clinical recheck. Ask your doctor to arrange confirmation.
Clinical panels from labs such as Invitae, Ambry, Color/Quest, or Myriad sequence the entire gene and are ordered through your care team. If your 23andMe report mentioned MUTYH, treat it as a prompt to call a genetic counselor, not as a final answer.
Section recap: A 23andMe MUTYH report checks only two variants and is not diagnostic. Confirm any consumer result with full clinical gene sequencing ordered by a clinician.
Interpreting Your Results: Diagnosis, Carrier, or Uncertain
My report used the phrase “variant of uncertain significance.” Does that mean I’m probably sick?
No, it means “unknown,” not “positive.” Under ACMG classification logic a VUS has not accumulated enough evidence to call it harmful, and on its own it should not drive aggressive treatment.
Once a clinical test comes back, the wording matters. Three broad outcomes are possible, and each points to a very different path.
- Two pathogenic variants = a MAP diagnosis. This is the biallelic, high-risk situation that needs a surveillance plan.
- One pathogenic variant = a carrier. You can pass the variant to children, but your own risk is low.
- A variant of uncertain significance (VUS) = a DNA change whose meaning is unknown. On its own, a VUS should not trigger surgery or aggressive screening.
Laboratories classify variants using ACMG logic, which weighs many lines of evidence — how often a change appears in healthy people, how it affects the protein, and whether families with it develop disease. A VUS simply means that evidence has not yet added up to a clear answer, and it may be reclassified later.
Think of a VUS like a word your spell-checker underlines but cannot confidently mark right or wrong. You would not rebuild the whole sentence around it. This is exactly why a certified genetic counselor, not a phone app, should interpret ambiguous results. Find one at NSGC.org.
So who’s supposed to actually explain a confusing result like that to me?
A certified genetic counselor, whom you can find at NSGC.org, since the NSGC position statements say ambiguous results belong with a trained professional, not a phone app. Ask your doctor for that referral.
Section recap: Two pathogenic variants mean MAP; one means carrier; a VUS means “unknown,” which should not by itself drive surgery. A genetic counselor should interpret the result.
Colonoscopy Surveillance and Early Detection
If my risk is really that high, isn’t a colonoscopy every few years way too little?
Frequent enough is the key idea, and GeneReviews recommends colonoscopy every one to two years for biallelic carriers. Catching and removing polyps early is exactly what turns a high statistical risk into a manageable one.
For confirmed biallelic MAP, surveillance is the cornerstone of care. Catching and removing polyps early is what turns a high statistical risk into a manageable one.
GeneReviews summarizes the recommended schedule for biallelic carriers:
| Procedure | Start age | Interval | Why |
|---|---|---|---|
| Colonoscopy | 25–30 years | Every 1–2 years | Find and remove colon polyps early |
| Upper endoscopy / duodenoscopy | 30–35 years | Every 3 months to 4 years | Duodenal adenomas occur in 17–34%; duodenal-cancer risk ~4% |
The upper-GI check matters because MAP is not limited to the colon. Duodenal (upper-intestine) polyps appear in 17% to 34% of affected people, and the lifetime risk of duodenal cancer is about 4%.
Exact ages and intervals are individualized — your care team sets them based on your polyp count and history. Monoallelic carriers are handled differently. The ACG/USMSTF guideline offers, as one option, managing a single carrier like someone with a first-degree relative who had colon cancer: colonoscopy every 5 years, starting 10 years before the earliest family diagnosis.
What should I actually bring, and who sets my exact schedule and start age?
Bring your family history to your gastroenterologist or genetic counselor, who individualizes it, since the ACG guideline ties monoallelic screening to the earliest family diagnosis. They set your interval, not a fixed rule.
A useful analogy: surveillance is like servicing a car on a schedule. You are not waiting for a breakdown; you are catching small problems before they grow. Bring your family history to your gastroenterologist or genetic counselor so they can set your interval.
Section recap: Biallelic MAP typically means colonoscopy every 1–2 years from the mid-to-late 20s, plus upper-GI checks. Monoallelic carriers usually follow a lighter, family-history-based schedule.
Prevention, Chemoprevention, and Prophylactic Surgery
Couldn’t I just take a daily aspirin and skip all the invasive stuff?
I understand the appeal, but the ACG guideline treats aspirin-type chemoprevention as still investigational for MAP. The proven benefit lies in colonoscopy and polyp removal, not in a pill.
Management goes beyond watching. It runs along a spectrum, and every step should be tied to what the evidence supports.
- Polypectomy — removing polyps during colonoscopy — is the routine first line and the reason regular surveillance works.
- Colectomy — surgery to remove part or all of the colon — is considered when the polyp burden grows too large to manage endoscopically.
- Chemoprevention with aspirin or other NSAIDs is more limited and still investigational for MAP; the proven benefit lies in colonoscopy, not pills.
It helps to separate what is established from what is not. Colonoscopy-based detection and removal have solid guideline backing. Drug-based prevention does not yet carry the same weight and should never replace surveillance.
Lifestyle steps — quitting smoking and general colon-cancer risk reduction — are worth doing as adjuncts, not substitutes, for monitoring. They lower background risk but do not fix the underlying repair defect.
So how do I know if or when I’d ever actually need surgery on my colon?
GeneReviews reserves colectomy for when the polyp burden outgrows endoscopic control, so it is not automatic. A gastroenterologist and genetic counselor who know your case should make that call together.
Every management choice here — when to operate, whether to try chemoprevention — belongs to a specialist who knows your case. A gastroenterologist and genetic counselor should co-manage the plan.
Section recap: Polypectomy is routine, colectomy is reserved for heavy polyp burden, and chemoprevention remains investigational. Lifestyle steps help but do not replace surveillance.
Family Implications and Cascade Testing
If I turn out biallelic, are my kids and my brother just doomed to have it too?
Not doomed, and the recessive math is reassuring. MedlinePlus explains your children would be at least carriers, but whether they are affected depends on your partner’s genes too. This section spells out the numbers.
Because MAP is recessive, the math for relatives follows clear rules — and understanding it can calm a lot of fear.
- A biallelic person’s children are all at least carriers (obligate monoallelic), because that parent passes on one broken copy for certain.
- Whether a child is biallelic depends on whether the other parent also carries a MUTYH variant.
- Siblings of a biallelic person have a 25% chance of being biallelic themselves.
To put the sibling number plainly: out of four siblings of a person with MAP, on average one would be biallelic, two would be single carriers, and one would carry neither copy. Real families vary, but that is the expected split.
This is where cascade testing comes in — systematically offering testing to at-risk relatives once a family’s specific variant is known. Starting from that known variant makes each relative’s test cheaper and clearer, because the lab knows exactly what to look for. The NSGC supports family health history and cascade testing coordinated through genetic counseling.
How do I even bring this up with my brother without totally freaking him out?
A genetic counselor can help you script it, and the NSGC supports family health history and cascade testing coordinated through counseling. Frame it as shared information plus an available test, not alarming news.
A genetic counselor can also help you script these conversations. Consider raising it with siblings and adult children as shared information — “our family carries this, and testing is available” — rather than as alarming news.
Section recap: A biallelic person’s children are all at least carriers; siblings have a 25% chance of being biallelic. Cascade testing from a known family variant is cheaper, clearer, and best coordinated through counseling.
Psychosocial Impact: GINA, the Insurance Gap, and Disclosure
Honestly, my biggest fear is that a positive test wrecks my insurance or my job.
That is one of the most common fears, and there is real protection. The 2008 GINA law bars US health insurers and employers from using genetic results against you, though it does leave one gap.
Many readers worry less about biology and more about consequences — jobs, insurance, and family reactions. Here the US and Canada differ, so both are covered.
In the US, the Genetic Information Nondiscrimination Act (GINA, 2008) protects you in two arenas:
- Health insurers cannot use genetic information for eligibility, coverage, underwriting, or premiums, and cannot require testing.
- Employers cannot use genetic information in hiring, firing, promotion, pay, or job assignment.
But GINA has a real, important gap. Its protections do not cover life insurance, disability insurance, or long-term-care insurance. That is a genuine limitation readers should weigh before applying for those products. Some US states have passed laws extending protection to these lines.
Canada goes further. The Genetic Non-Discrimination Act (2017) bars anyone — including insurers — from requiring a person to take or disclose a genetic test as a condition of a contract or service. The Supreme Court of Canada upheld the Act in a 5-4 decision on July 10, 2020. This gives Toronto-area and other Canadian readers broader insurance coverage than US GINA.
| Protection | US (GINA, 2008) | Canada (GNDA, 2017) |
|---|---|---|
| Health insurance | Protected | Protected |
| Employment | Protected | Protected |
| Life / disability / long-term-care | Not covered | Broadly covered |
So before I sign up for any life insurance, who should I actually talk to about timing?
A genetic counselor, whom you can reach via NSGC.org, since GINA leaves life, disability, and long-term-care insurance uncovered. Discuss timing with them before you apply for those specific policies.
The emotional side is real too. Sharing hereditary risk with siblings and adult children can stir guilt, worry, or conflict. A genetic counselor can support these conversations and help each family member decide about testing on their own timeline.
Section recap: GINA blocks genetic discrimination in US health insurance and employment but leaves life, disability, and long-term-care insurance uncovered. Canada’s 2017 law closes more of that gap. Genetic counseling supports family disclosure.
Frequently Asked Questions
Will I get the disease if my brother has MUTYH-associated polyposis? Not automatically. MAP is recessive, so you would need two broken MUTYH copies to have it. As a sibling of a biallelic person, you have a 25% chance of being biallelic yourself. Clinical testing is the only way to know — ask a genetic counselor.
Does having one MUTYH mutation mean I’ll get colon cancer? No. A single (monoallelic) mutation carries, at most, a small and uncertain increase over baseline — the pooled odds ratio was 1.15 with a confidence interval that crosses 1.0. Most single carriers are not managed as high-risk.
Will this affect my health or life insurance? In the US, GINA blocks health insurers and employers from using genetic results against you, but it does not cover life, disability, or long-term-care insurance. In Canada, the 2017 Genetic Non-Discrimination Act covers more, including insurance contracts. Discuss timing with a genetic counselor before applying for uncovered policies.
Can my employer find out? Under US GINA, employers cannot use genetic information in hiring, firing, pay, or promotion, and cannot require it. Canada’s law similarly bars employers from demanding genetic information.
Should I get a second opinion or clinical confirmation? Yes, if your result came from a consumer test. A 23andMe report checks only two variants and is not diagnostic, and 40% of DTC risk variants were false positives on clinical recheck in one study. Confirm any result with a clinician and certified genetic counselor.
Summary
MUTYH-associated polyposis has a clear scientific backbone and one honest area of uncertainty. Since the 2002 discovery of the repair defect, research has shown that biallelic carriers face a high lifetime colon-cancer risk — 80–90% without surveillance — while monoallelic carriers face, at most, a small and debated increase. Guideline-based colonoscopy is the proven cornerstone of care. A consumer DNA report is a screen, not a diagnosis, and every real decision — testing, interpretation, surveillance, disclosure — belongs with a clinician and a certified genetic counselor. In the US, GINA protects health insurance and jobs but leaves life and disability insurance exposed; Canada’s 2017 law covers more. Knowing your real numbers, in absolute terms, is the first step toward a plan you can act on calmly.
This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.
References
- Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nature Genetics 2002;30:227–232. https://pubmed.ncbi.nlm.nih.gov/11818965/
- Nielsen M, Infante E, Brand R, et al. MUTYH Polyposis (MUTYH-Associated Polyposis). GeneReviews®, University of Washington (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK107219/
- MedlinePlus Genetics (NIH/NLM). MUTYH-associated polyposis / MUTYH gene. https://medlineplus.gov/genetics/condition/mutyh-associated-polyposis/
- Syngal S, Brand RE, Church JM, et al. ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. Am J Gastroenterol 2015;110(2):223–262. https://pubmed.ncbi.nlm.nih.gov/25645574/
- Win AK, Hopper JL, Jenkins MA. Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 2011;10(1):1–9. https://pmc.ncbi.nlm.nih.gov/articles/PMC3228836/
- US FDA. 23andMe PGS Genetic Health Risk Report for MUTYH-Associated Polyposis, 510(k) K182784 (cleared 2019-01-22). https://www.accessdata.fda.gov/cdrh_docs/reviews/K182784.pdf
- Tandy-Connor S, Guiltinan J, Krempely K, et al. False-positive results released by direct-to-consumer genetic tests. Genet Med 2018;20(12):1515–1521. https://pubmed.ncbi.nlm.nih.gov/29565420/
- National Cancer Institute. Genetics of Colorectal Cancer (PDQ®) — Health Professional Version. https://www.ncbi.nlm.nih.gov/books/NBK126744/
- National Human Genome Research Institute. Genetic Discrimination and the Genetic Information Nondiscrimination Act of 2008 (GINA). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
- Reference re Genetic Non-Discrimination Act, 2020 SCC 17 (Genetic Non-Discrimination Act, S.C. 2017, c. 3). https://en.wikipedia.org/wiki/Reference_re_Genetic_Non%E2%80%91Discrimination_Act
- National Society of Genetic Counselors (NSGC). Consumer-Initiated / At-Home Genetic Testing and Family Health History position statements. https://www.nsgc.org/Advocacy/Position-Statements/Position-Statements/Post/consumer-initiated-genetic-testing-position-statement
- Win AK, Cleary SP, Dowty JG, et al. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 2011. https://pubmed.ncbi.nlm.nih.gov/21171015/
Last updated: 2026-07-11
Author: genelumen editorial team. This article aggregates 12 sources from peer-reviewed medical literature and public health agencies (tier 1=8 / tier 2=4), including NIH, the National Cancer Institute, the FDA, ACG/USMSTF and NSGC guidelines, and PubMed-indexed publications. Editorial responsibility: Yu Mizuno, a non-physician research editor.
This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).
Related: Hereditary Cancer category
🇯🇵 For readers in Japan — a separate Japanese edition written for Japan’s healthcare system (not a translation): https://genelumen.com/ja/ja-hereditary-cancer/mutyh-associated-polyposis-colorectal-japan
